NTBLQ (Notable Labs) Total Receivables: $0.18 Mil (As of Jun. 2024)


What is Notable Labs Total Receivables?

Notable Labs NTBLQ -90.00% Total Receivables is $0.18 Mil as of Jun. 2024.

Notable Labs's Total Receivables for the quarter that ended in Jun. 2024 was $0.18 Mil.

Notable Labs Total Receivables Historical Data

* Premium members only.

The historical data trend for Notable Labs's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs Total Receivables Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
0.05 0.01 0.19

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Total Receivables Get a 7-Day Free Trial 0.00 0.00 0.19 0.18 0.18

Notable Labs Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.18 Mil mean?
Notable Labs (NTBLQ) has a Total Receivables of $0.18 Mil as of Jun. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Notable Labs and its competitors.
Is Notable Labs' Total Receivables too high?
Notable Labs' current Total Receivables is $0.18 Mil.
How does Notable Labs' Total Receivables compare to VRTX and REGN?
Notable Labs' Total Receivables of $0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Notable Labs and its competitors. Notable Labs's current Total Receivables is $0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current Total Receivables of $0.18 Mil. The current Total Receivables is $0.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current Total Receivables is $0.18 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.